Equities

Axsome Therapeutics Inc

Axsome Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)90.07
  • Today's Change-0.63 / -0.69%
  • Shares traded635.29k
  • 1 Year change+46.31%
  • Beta1.1570
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy6
Outperform11
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 16 analysts offering 12 month price targets for Axsome Therapeutics Inc have a median target of 117.50, with a high estimate of 180.00 and a low estimate of 71.00. The median estimate represents a 30.45% increase from the last price of 90.07.
High99.8%180.00
Med30.5%117.50
Low-21.2%71.00

Earnings history & estimates in USD

On Aug 05, 2024, Axsome Therapeutics Inc reported 2nd quarter 2024 losses of -1.67 per share.
The next earnings announcement is expected on Nov 12, 2024.
Average growth rate-7.12%
Axsome Therapeutics Inc reported annual 2023 losses of -5.27 per share on Feb 20, 2024.
Average growth rate-27.55%
More ▼

Revenue history & estimates in USD

Axsome Therapeutics, Inc. had 2nd quarter 2024 revenues of 87.17m. This bettered the 86.92m consensus of the 16 analysts covering the company. This was 7.83% below the prior year's 2nd quarter results.
Average growth rate+17.61%
Axsome Therapeutics, Inc. had revenues for the full year 2023 of 270.60m. This was 440.80% above the prior year's results.
Average growth rate+146.93%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.